RxDoctor Payments Data

John Albertini, MD

Urology · Eureka, CANPI 1528087632

Payments from drug & device makers

$5,512in general payments, 2019–2025

Across 51 payments — averaging $108.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Neotract Inc.$1K
  • Boston Scientific$275
  • AbbVie$205
  • Pfizer$102
  • Procept Biorobotics Corporation$88
  • plus $153 from 5 others

What the payments were for

  • Travel & lodging$2,65648%
  • Food & beverage$1,35525%
  • Education$1,50027%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical11$3,549
Neotract Inc.9$1,140
Boston Scientific8$275
AbbVie(2 entities)11$205
Pfizer2$102
Procept Biorobotics Corporation4$88
Ferring Pharmaceuticals Inc.2$50
Progenics Pharmaceuticals, Inc.1$29
180 Medical, Inc.1$28
Astellas Pharma US Inc1$25
Dornier Medtech America, Inc1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,512 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$465,123
Medicare patients
954
Services billed
13,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron95$69,736
Potassium Citrate ErPotassium Citrate77$7,656
Tamsulosin Hcl392$7,475
Methenamine Hippurate67$5,431
Finasteride270$3,988
Bicalutamide96$1,882
Estradiol17$802
Alfuzosin Hcl ErAlfuzosin Hcl51$797
CefuroximeCefuroxime Axetil45$446
Testosterone Cypionate14$434
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$380
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$311
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen71$280
Solifenacin Succinate14$262
Ampicillin Trihydrate22$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$25$69,73695 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Eureka

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →